VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PAVSParanovus Entertainment Technology Ltd.
$0.07$4059
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPAVSFinancials

Paranovus Entertainment Technology Ltd. (PAVS) Financials

9Y historyFree accessUpdated daily

The company exhibits extreme operational inefficiency, evidenced by SG&A expenses that consistently dwarf gross profit, resulting in a 2025Q2 operating margin of -5.1%.

PAVS Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMMar'25Mar'24Mar'23Mar'22Mar'21Mar'20Mar'19Mar'18Mar'17
Sales/Revenue12.74M71.54K6.54M23.33M20.76M71.48M65.06M63.94M61.5M53M
Revenue Growth %-82.37%-98.91%-71.95%12.4%-70.96%9.87%1.76%3.97%16.04%-
Cost of Goods Sold11.32M62.53K6.54M22.92M85.78M53.31M34.64M31.69M32.14M27.18M
COGS % of Revenue-87.4%99.86%98.21%413.21%74.57%53.25%49.56%52.27%51.29%
Gross Profit1.41M9.02K9.14K416.88K3.71M18.18M30.42M32.25M29.35M25.82M
Gross Margin %11.08%12.6%0.14%1.79%17.88%25.43%46.75%50.44%47.73%48.71%
Gross Profit Growth %--1.37%-97.81%-88.77%-79.58%-40.25%-5.67%9.86%13.69%-
Operating Expenses26.19M6.79M4.63M4M51.29M16.65M15.02M10.4M9.11M8.61M
OpEx % of Revenue-9494.53%70.76%17.15%247.07%23.29%23.09%16.27%14.82%16.25%
Selling, General & Admin5.57M2.31M2.46M4M11.42M14.99M12.66M8.24M7.25M6.96M
SG&A % of Revenue-3226.16%37.62%17.15%55.02%20.97%19.46%12.89%11.8%13.13%
Research & Development0001.4M1.68M1.66M2.36M2.16M1.86M1.66M
R&D % of Revenue---5.99%8.11%2.32%3.63%3.38%3.02%3.12%
Other Operating Expenses2M4.48M2.17M-1.4M38.18M00000
Operating Income-1.31M-6.78M-4.62M-4.55M-11.17M1.53M15.4M21.84M20.24M17.21M
Operating Margin %-10.28%-9481.93%-70.62%-19.5%-53.79%2.13%23.67%34.16%32.91%32.47%
Operating Income Growth %--46.78%-1.6%59.26%-831.79%-90.09%-29.5%7.92%17.64%-
EBITDA531.77K-6.4M-4.24M-4.49M-8.98M2.41M16.07M22.53M20.36M17.33M
EBITDA Margin %4.18%-8950.77%-64.79%-19.25%-43.25%3.37%24.7%35.23%33.11%32.7%
EBITDA Growth %101.05%-51.01%5.56%49.98%-473.05%-85.03%-28.64%10.63%17.48%-
D&A (Non-Cash Add-back)1.84M380K381.13K58.75K2.19M880.88K674.25K682.46K119.76K125.92K
EBIT-5.72M-6.74M-3.75M-4.53M-57.66M1.76M15.63M21.99M20.49M17.51M
Net Interest Income-483.23K-261.7K-38.82K022.4K20.1K-23.16K-41.51K-114.57K-482.1K
Interest Income156156345316108.39K131.9K74.93K42.04K18.71K11.62K
Interest Expense483.39K261.85K39.17K72.3K85.99K111.8K98.09K83.55K133.28K493.73K
Other Income/Expense-19.81M-219.09K831.48K22.04K965.74K125.62K133.41K62.26K120.85K-184.66K
Pretax Income-21.12M-7M-3.79M-4.53M-10.2M1.65M15.53M21.91M20.36M17.02M
Pretax Margin %-165.86%-9788.16%-57.91%-19.4%-49.13%2.31%23.87%34.26%33.11%32.12%
Income Tax0003K696959.38K2.84M3.18M2.87M2.5M
Effective Tax Rate %0%0%0%-0.07%-0.01%58.1%18.31%14.53%14.1%14.72%
Net Income-26.9M-7.89M-10.13M-71.74M-49.19M786.36K12.69M18.72M17.49M14.52M
Net Margin %-211.19%-11033.03%-154.72%-307.47%-236.96%1.1%19.5%29.28%28.44%27.39%
Net Income Growth %73.81%22.05%85.88%-45.84%-6355.51%-93.8%-32.23%7.04%20.49%-
Net Income (Continuing)-21.12M-7M-3.79M-4.53M-54.02M691.96K12.69M18.72M17.49M14.52M
Discontinued Operations-2.3M-1.3M-6.14M-67.66M000000
Minority Interest4.84M4.75M-412.18K-886.01K-710.75K2.89M0000
EPS (Diluted)-381.90-93.60-2568.00-15156.00-29160.0036.0012720.0017976.0016788.0013932.00
EPS Growth %76.72%96.36%83.06%48.02%-81100%-99.72%-29.24%7.08%20.5%-
EPS (Basic)--93.60-2568.00-15156.00-29160.0036.0012720.0017976.0016788.0013932.00
Diluted Shares Outstanding70.43K70.43K3.94K4.73K1.69K21.8K9931.04K1.04K1.04K
Basic Shares Outstanding70.43K70.43K3.94K4.73K1.69K21.8K9931.04K1.04K1.04K
Dividend Payout Ratio--------47.63%-

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Existential Going Concern Risk

Revenue Collapse Signals Operational Failure

According to historical financial filings, PAVS experienced a catastrophic 98.9% year-over-year revenue decline, effectively signaling the abandonment of its legacy nutraceutical business model and leaving the firm with negligible top-line contributions that suggest a near-total cessation of core commercial activities across its reported operating segments.

The precipitous drop in revenue from historical levels of over $40 million per quarter to current nominal figures indicates that the company's pivot to entertainment technology has failed to gain any meaningful traction. This trajectory suggests that the entity is no longer functioning as a viable commercial enterprise in its original industry, warranting extreme caution regarding future revenue durability.

Structural Margin Erosion Remains Persistent

As reported in recent income statements, the company's gross margin has fluctuated near the low double-digits, with a 12.6% average reflecting significant pricing pressure and an inability to maintain the premium spreads typically associated with specialized nutraceutical products in a competitive Chinese market environment.

The inability to sustain healthy gross margins suggests that the company lacks the pricing power necessary to offset rising raw material costs or competitive encroachment. This margin profile appears structurally compromised, as the current cost of goods sold consistently consumes the vast majority of the limited revenue generated.

Operating Leverage Remains Severely Distorted

Based on the provided financial data, the company exhibits extreme operating inefficiency, with SG&A expenses consistently dwarfing gross profit, leading to massive operating losses that indicate a failure to achieve any semblance of scale or cost discipline throughout its recent corporate restructuring and rebranding efforts.

The persistent gap between operating expenses and gross profit suggests that the company's fixed cost base is entirely misaligned with its current revenue reality. Investors should monitor whether management can implement drastic cost-cutting measures, though the current data suggests that operating leverage remains deeply negative and unsustainable.

Distressed Asset or Shell Potential

While the income statement reflects a failing operating business, the market may be pricing the entity as a potential shell for future reverse mergers, yet the reported cash balance of $261,355 suggests that the company lacks the liquidity to sustain even basic regulatory compliance requirements.

Short-term observers might argue that the company's US listing status holds residual value, but the financial evidence points toward an entity that is rapidly depleting its remaining capital. The lack of a clear path to profitability or operational stabilization suggests that the current valuation may be disconnected from the underlying reality of its distressed financial position.

PAVS — Frequently Asked Questions

Quick answers to the most common questions about buying PAVS stock.

What was Paranovus Entertainment Technology Ltd.'s (PAVS) revenue in 2024?

For fiscal year 2024, Paranovus Entertainment Technology Ltd. (PAVS) reported total revenue of $0.1M. This represents a 99.9% decline compared to $53.0M in 2016.

Is Paranovus Entertainment Technology Ltd. (PAVS) profitable?

Paranovus Entertainment Technology Ltd. (PAVS) reported a net loss of $7.9M for the fiscal year ending 2024.

What is Paranovus Entertainment Technology Ltd.'s operating profit margin?

Paranovus Entertainment Technology Ltd. (PAVS) reported an operating income of $-6.8M, resulting in an operating profit margin of -9481.9%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Paranovus Entertainment Technology Ltd.'s gross profit and gross margin?

Paranovus Entertainment Technology Ltd. (PAVS) generated $0.0M in gross profit for the year, representing a gross profit margin of 12.6%. This demonstrates the company's core pricing power and production efficiency.